𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients

✍ Scribed by Swapna Verma; Mythily Subramaniam; Edimansyah Abdin; Kang Sim; Alex Su; Nelson Lee; Siow Ann Chong

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
104 KB
Volume
25
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders.

Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior oral risperidone run‐in phase. Efficacy was assessed by the positive and negative syndrome scale (PANSS) and clinical global impression (CGI) scales. Extra‐pyramidal side effects (EPSE) was assessed using the Simpson Angus Scale (SAS), and weight and plasma levels of fasting blood glucose, lipids and prolactin were measured. Baseline and last visits differences were tested by paired t‐test and Wilcoxon signed‐rank test; ratings measured over time were analysed using repeated measures ANOVA.

Participants' mean age was 30.3 (±6.6) years. Principal reason for switching to LAR was non‐compliance (40.0%). Thirteen (52%) patients completed the trial. Over 6 months, there were significant reductions in total PANSS (p = 0.008) and CGI (p = 0.001) scores. There were significant increases in weight (p < 0.001), levels of plasma cholesterol and fasting glucose.

LAR was effective in improving symptom severity within the first month of starting treatment. However, significant increases in weight and plasma levels of fasting glucose and cholesterol raise concern about metabolic side effects. Copyright © 2010 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Efficacy and safety of long-acting rispe
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
✍ Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerd 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 1 views

## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi

A comparison of the efficacy and safety
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration
✍ C. W. Ritchie; E. Chiu; S. Harrigan; S. Macfarlane; M. Mastwyk; G. Halliday; H. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect

A pilot, randomized, open-label trial as
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances
✍ Mark Weiser; Heschi H. Rotmensch; Amos D. Korczyn; Richard Hartman; Ana Cicin-Sa 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## Background The majority of patients with Alzheimer's disease (AD) or vascular dementia display, in addition to cognitive impairment, various degrees of behavioral disturbances. As the use of cholinesterase inhibitors for the treatment of cognitive impairment in dementia becomes wide

The acute and long-term effectiveness of
The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study
✍ Yong Min Ahn; Kyu Young Lee; Chul-Eung Kim; Dae-Yeob Kang; Jeong-Ho Seok; Young 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

## Objective To compare the effectiveness of amisulpride in acute (up to 8 weeks) and maintenance (week 8 to 12 months) phases of a 12‐month course of treatment in a heterogeneous group of patients with schizophrenia. ## Methods We conducted a 12‐month, open‐label clinical trial with flexible dos